Filsuvez recommended for use in NHS to treat EB

Filsuvez recommended for use in NHS to treat EB

The National Institute for Health and Care Excellence (NICE) have recommended Filsuvez for the treatment of open wounds in junctional and dystrophic epidermolysis bullosa. Filsuvez is a gel containing a dry extract from two species of birch bark, and is applied to the surface of wounds.

Developed by Amryt Pharma this is the first approved treatment for EB in the UK, and marks a milestone in bringing treatments forward for patients with EB.

While not a cure we are hopeful that it will improve the quality of life for patients by closing wounds more quickly. We are grateful for Amryt’s dedication in bringing this treatment forward and look forward to being able to use it.

Healing open wounds in junctional and dystrophic epidermolysis bullosa faster will improve the quality of life for our children and adults with EB. We look forward to a future with more treatment options coming through soon!

Read The Times article on the NICE recommendation.